Preface

This summary is adjunctive to conventional primary and secondary care. Across all evidence tiers, the single unambiguous, high-certainty intervention is progressive resistance exercise training (RET), optimally combined with protein/amino-acid supplementation.[1][2][3] Every pharmacological or “geroscience” agent below is currently off-label or investigational for sarcopenia — no drug has regulatory approval for this indication anywhere.[3][1][4]

The following algorithm from the Nature Reviews Disease Primers Sarcopenia primer anchors the care pathway (diagnosis → offer RET → consider protein → comprehensive geriatric assessment / trial enrolment):

Figure 5 Algorithm for management of sarcopenia. This algorithm outlines the different management strategies that may currently be followed after sarcopenia is diagnosed dependent on whether or not resistance exercise training (RET) is offered and the age of the person diagnosed.



1. Scope

– Covered: Assessment (EWGSOP2/AWGS-based case-finding and diagnosis) and interventions to prevent or reverse age-related loss of muscle mass, strength and physical performance in a private UK longevity clinic. Includes exercise, nutrition/supplements (protein, leucine, HMB, creatine, vitamin D, omega-3), and off-label/emerging pharmacology (testosterone, myostatin/activin pathway inhibitors, SARMs, NAD⁺ precursors, metformin), plus muscle-preservation strategies during GLP-1-based weight loss.

– Not covered: Primary cachexia of advanced malignancy/organ failure (specialist palliative/oncology remit), inherited myopathies, and disease-specific rehabilitation (e.g. post-stroke).

– Positioning: Content is adjunctive to, not a replacement for, NHS primary/secondary care. Diagnosis and red-flag work-up should align with conventional pathways.

2. Background and pathophysiology

– Sarcopenia is a progressive muscle disease (“muscle failure”) accruing across the lifespan; it is a recognised WHO disease entity and predicts falls, fractures, disability and mortality.[6][7]

– Best-evidenced human mechanisms: anabolic resistance (blunted muscle protein synthesis to protein/exercise), chronic low-grade inflammation (“inflammaging”, raised IL-6/TNF-α), age-related decline in testosterone/IGF-1, motor-unit/neuromuscular junction loss, and mitochondrial dysfunction.[8][7]

– Mechanistic-plausibility-only / geroscience targets (extrapolated from the hallmarks-of-aging framework, human data limited): cellular senescence burden (senolytics), NAD⁺ decline, and metabolic reprogramming (metformin).[9]

Preclinical only (do not use to justify clinical decisions): NAD⁺-replenishing mitochondria-targeted delivery systems, myostatin gene editing, AAV/IGF-1 and stem-cell approaches — rodent/in-vitro evidence with no controlled human sarcopenia outcome data.[10][8][7]

3. Evidence base and grading

Available evidence comprises multiple RCTs and network meta-analyses for exercise/nutrition, mostly phase II RCTs for pharmacology, and cohort data for biomarker associations. Most drug trials did not enrol biopsy/criterion-defined sarcopenic patients (serious indirectness), and improvements in muscle mass frequently fail to translate into functional gains.[1][4]

Intervention / outcome	Evidence statement (GRADE certainty)	Key limitations	Strength of recommendation	Ref
Resistance + balance training + protein → strength, mass, function	Network MA, 96 RCTs, n≈7,596; gait speed +0.20 m/s, SPPB +3.59, exceeding MCID (High)	Heterogeneous protocols	Strong — offer	[2]
Resistance exercise alone → strength/mass	Consistent RCT/guideline evidence (Moderate–High)	Fewer trials in criterion-defined sarcopenia	Strong — offer	[1], [3]
Protein 1.0–1.5 g/kg/day ± leucine	Conditional consensus; adjunctive to exercise (Moderate)	Inconsistent as monotherapy	Conditional — offer with exercise	[3], [11]
Creatine monohydrate + RET → lean mass, strength	MAs (RET-combined, n≈357; broader n≈1,076) show added lean mass/strength; quality low–moderate (Low–Moderate)	Small trials, risk of bias	Conditional — consider adjunct to RET	[12], [13], [14]
Omega-3 (EPA+DHA >2 g/day) → strength; mass variable	Several RCTs + MAs; small clinically-relevant strength gain (Low–Moderate)	Heterogeneity; MAPT null as monotherapy	Conditional — consider, best with RET	[15], [16], [17], [18]
HMB → mass/strength preservation	Position-paper supported, limited trials (Low)	Small studies	Conditional — consider (esp. illness/immobility)	[3]
Vitamin D → strength	Benefit largely confined to deficiency (<25–50 nmol/L) (Low; High for no mobility benefit if replete)	Indirect; deficiency-dependent	Conditional — correct deficiency only	[3], [11][1]
Testosterone (hypogonadal men) → mass > strength/function	RCTs incl. Testosterone Trials; limited functional benefit, CV caution (Moderate for mass)	Not sarcopenia-defined; CV safety	Only if hypogonadal; recommend against for sarcopenia per se	[1], [3]
Bimagrumab (anti-ActRII) → thigh muscle volume, fat loss	Phase II RCT, well tolerated; gait-speed signal only in slow walkers (Low, surrogate)	No confirmed functional/hard outcome	Only in research	[1], [19]
Myostatin inhibitors (apitegromab/trevogrumab) for lean-mass preservation with GLP-1	Phase II (EMBRAZE) preserved ~1.9 kg lean mass vs placebo (Low, surrogate)	Short-term, surrogate endpoint	Only in research	[20], [21]
SARMs → mass	Small phase I/II; larger trials unconvincing (Very low)	Safety, no function benefit	Recommend against outside trials	[1]
NMN / NR (NAD⁺ precursors) → muscle mass/function	Systematic review/MA: no consistent muscle benefit (Very low)	Small, surrogate-focused	Only in research	[22]
Metformin / senolytics (geroscience) → muscle/healthspan	Preclinical + observational; RCTs ongoing (Very low for sarcopenia)	No sarcopenia RCT endpoints	Only in research	[9]

Publication bias: likely for small supplement and early-phase pharma trials; effect sizes should be read conservatively.

4. Patient selection and indications

– Who may benefit (offer assessment ± RET/nutrition):

– Adults ≥65 with low grip strength, slow gait (<0.8 m/s), low SARC-F, or self-reported functional decline.[6]

– Middle-aged adults (50–64) with risk factors — the AWGS 2025 update explicitly extends case-finding to this group to enable earlier intervention.[23]

– High-risk phenotypes: multimorbidity, recent hospitalisation/immobilisation, weight loss, cardiometabolic disease, and patients on GLP-1/dual incretin therapy (25–39% of weight lost may be fat-free mass).[24][25]

– Exclusion / specialist-input groups: undiagnosed weight loss or red-flag features (exclude malignancy, thyroid, inflammatory/neuromuscular disease first); severe CKD (protein-loading caution); for any androgen therapy — history of prostate/breast cancer, erythrocytosis, uncontrolled cardiovascular disease.

– Regulatory/ethical status: Exercise, protein, creatine, omega-3 and vitamin D correction are evidence-based adjunctive care. All pharmacological agents are off-label; investigational biologics (bimagrumab, myostatin inhibitors, SARMs, NMN/NR, senolytics) should be restricted to clinical-trial frameworks or delivered only as documented, individualised off-label care with explicit informed consent.

5. Assessment and baseline work-up

– Case-finding & diagnosis (EWGSOP2): SARC-F ± calf circumference → grip strength (probable sarcopenia if low) → confirm low muscle quantity by DXA (appendicular lean mass) or BIA → severity by physical performance (gait speed, SPPB, TUG, 400 m walk). Note DXA lean mass correlates weakly with function; use performance measures for longitudinal monitoring.[6][1][3][26]

– History/exam: falls, nutrition/protein intake, weight trajectory, medications (steroids, GLP-1s), alcohol, activity; screen for depression/cognition and comorbidity per comprehensive geriatric assessment in older patients.[5][11]

– Baseline investigations: FBC, U&E/eGFR, LFTs, HbA1c, CRP, TSH, 25-OH vitamin D, and (if considering androgen therapy) morning testosterone/SHBG, PSA, haematocrit. Consider vitamin B12, coeliac screen if weight loss.

– Functional battery to document: grip strength, gait speed, SPPB, five-times sit-to-stand, and appendicular skeletal muscle mass index. Record these as the reference for follow-up (biomarkers such as GDF-15 remain research-only).[8]

– Risk stratification: low (isolated low grip, no falls) → high (confirmed/severe sarcopenia, recurrent falls, multimorbidity, on GLP-1). Harm-risk is highest for androgen/investigational agents in CV disease, malignancy history, or frailty.

6. Dosing regimens and practical implementation

Robust human-data-supported (recommend):

– Resistance training: progressive, 2–3 sessions/week, 8–12 exercises, working major muscle groups, ~30–60 min/session; add balance training; multicomponent (aerobic + resistance + balance) for broader function. RET + protein/amino-acid supplementation is the most effective single strategy.[2][11]

– Protein: 1.0–1.2 g/kg/day for healthy older adults; 1.2–1.5 g/kg/day in acute/chronic illness (avoid high loading in CKD); distribute ~25–30 g/meal, leucine-enriched or whey, ideally in temporal proximity to training.[3][11]

Reasonable adjuncts (consider — low/moderate certainty):

– Creatine monohydrate: ~3–5 g/day (no loading phase required); benefits are contingent on concurrent RET; post-exercise timing may modestly favour lean-mass gain.[12][13][14]

– Omega-3 (EPA+DHA): >2 g/day for a strength signal; effect most evident combined with RET; monotherapy is unreliable.[15][16][18]

– HMB: ~3 g/day, particularly during illness/immobilisation.[3]

– Vitamin D: correct deficiency to standard UK targets; no evidence for supra-physiological dosing to treat sarcopenia in replete individuals.[11][1]

Extrapolated / caution — investigational (do not use outside trials/structured off-label consent):

– Testosterone: only in confirmed male hypogonadism (serum <200–300 ng/dL), not as sarcopenia therapy; monitor CV risk, haematocrit, PSA.[3][1]

– Bimagrumab / myostatin inhibitors / SARMs / NMN / NR / metformin / senolytics: dosing is trial-specific; no validated regimen for sarcopenia mitigation.[22][1][19][20][21][9]

7. Monitoring, safety and follow-up

– Monitoring parameters: grip strength, gait speed, SPPB/sit-to-stand, body composition (DXA/BIA), weight, and dietary protein adherence. Change in grip strength post-exercise is an unreliable short-term marker — prefer gait speed/SPPB.[26]

– Timepoints: reassess function at 8–12 weeks (early adaptation), 3–6 months, then 6–12 monthly. Repeat DXA no more often than ~6–12 monthly.

– Safety by intervention:

– Exercise/protein/creatine/omega-3: excellent tolerability; creatine may cause transient weight gain/GI upset (well tolerated in trials); high-dose omega-3 — bleeding caution with anticoagulants; protein loading — caution in CKD.[27][13]

– Testosterone: erythrocytosis, cardiovascular signal, prostate effects — check haematocrit and PSA; stop/reduce for HCT >54%.[1]

– Bimagrumab (phase II): muscle spasms, diarrhoea, falls; serious AEs 12.4% vs 7.5% placebo (none deemed drug-related); no clinically meaningful ECG/echo changes over 24 weeks.[19]

– NAD⁺ precursors: generally tolerated but no proven muscle benefit; long-term safety unknown.[22]

– Actions for abnormal findings: functional decline despite adherence → intensify supervised RET, reassess nutrition, exclude new pathology, refer to geriatrics. Any serious AE on off-label pharmacology → stop and reassess.

– Interactions: androgens with anticoagulants (INR effects) and erythropoiesis; omega-3 additive bleeding risk; protein/creatine caution in renal impairment; polypharmacy review (STOPP/START, Beers) is itself an evidence-based frailty intervention.[11]

– Special populations: pregnancy/breastfeeding — androgens and investigational agents contraindicated; renal impairment — cap protein, use creatine cautiously; hepatic impairment — caution with androgens; frailty/extreme age — favour supervised RET + protein and comprehensive geriatric assessment over pharmacology.[5][11]

8. Contraindications and cautions

– Absolute: testosterone/SARMs in active prostate or breast cancer, uncontrolled polycythaemia, or pregnancy; investigational biologics outside an approved trial without valid informed consent.

– Relative / specialist advice: androgens with established cardiovascular disease, untreated OSA, or high baseline haematocrit; high-protein regimens in advanced CKD; high-dose omega-3 with anticoagulation.

– Harm likely to outweigh benefit with current evidence: SARMs and NAD⁺ precursors for sarcopenia; any drug substituted in place of resistance exercise — pharmacology raises muscle mass without reliably improving function.[1][4]

9. Practical management scenarios

Scenario A — Middle-aged adult (50–64) with cardiometabolic risk factors. Offer (strong).

– Assessment: SARC-F, grip strength, gait speed; DXA; metabolic labs, vitamin D.

– Shared decision/consent: frame RET + protein as first-line, evidence-based.[2][23]

– Initiation: supervised progressive RET 2–3×/week + protein 1.0–1.2 g/kg/day; correct vitamin D; consider creatine 3–5 g/day and omega-3 >2 g/day as adjuncts.[12][15]

– Monitoring: function at 12 weeks, DXA at 6 months.

– Escalate/stop: no functional gain despite adherence → review technique/nutrition, exclude occult disease.

Scenario B — Older, frail patient with multimorbidity. Offer tailored RET; avoid pharmacology (conditional).

– Assessment: comprehensive geriatric assessment, falls and medication review (STOPP/START).[5][11]

– Consent: emphasise fall-reduction and independence goals.

– Initiation: supervised multicomponent (resistance + balance) exercise + protein 1.2–1.5 g/kg/day (renal-adjusted); ± HMB during intercurrent illness.[3][11]

– Monitoring: gait speed/SPPB and falls at 8–12 weeks; caution with polypharmacy.

– Escalate/refer: recurrent falls or rapid decline → geriatrics/falls service. Androgens/investigational drugs generally inappropriate.

Scenario C — Patient on GLP-1/dual-incretin therapy for obesity (adjunct to specialist care). Offer muscle-preservation strategy (strong for exercise/protein); myostatin inhibition research-only.

– Assessment: baseline DXA; note 25–39% of weight lost may be fat-free mass.[25][28]

– Initiation: structured resistance/mixed training (emphasis on strength) + protein-first meals, adequate protein intake; combined GLP-1 + exercise preserves lean mass and bone density better than GLP-1 alone.[29][24][30]

– Monitoring: DXA lean mass and strength at 6 months.

– Emerging option (research only): adjunct myostatin/activin inhibitors (apitegromab, trevogrumab, bimagrumab) preserved lean mass in phase II trials but have no functional/hard-outcome data and no approval.[20][21]

The phase II EMBRAZE trial illustrates the surrogate-endpoint nature of this emerging approach — additional lean-mass preservation, but not yet functional benefit:

Figure 2 Lean body mass preservation with apitegromab versus placebo at week 24 and week 32. Data are presented as least square mean (80% CI), based on a linear regression model controlling for baseline weight, baseline lean body mass, age and sex. a, For the primary endpoint (week 24), apitegromab preserved an additional 1.9 kg of lean mass compared to placebo (nominal, P = 0.0014). Two-sided P values are based on the t-statistic, considered descriptive, and no adjustments were made for multiple comparisons. b, At week 32, the difference in lean mass between apitegromab and placebo remained significant (least square mean (80% CI), 0.9 (0.3−1.5); nominal, P = 0.0480). LS, least square.

10. Research gaps and future directions

– Functional translation: most drugs increase muscle mass without proven gains in strength, physical function, falls or mortality — the central unresolved gap.[1][4]

– Criterion-defined populations: few trials enrol EWGSOP2/AWGS-defined sarcopenic patients; optimal exercise “dose” and protein timing remain undefined.[1][2]

– GLP-1 era: long-term functional consequences of incretin-associated fat-free-mass loss, and whether myostatin/activin inhibitors deliver functional (not just compositional) benefit, require adequately powered phase III trials.[20][25][28]

– Geroscience agents: NAD⁺ precursors, metformin (e.g. ongoing healthspan/frailty trials) and senolytics lack sarcopenia-specific RCT endpoints and should stay within trials/registries.[9][22]

– Priority: establish validated biomarkers and confirm hard clinical outcomes before adopting any pharmacological agent into routine longevity practice.

References

1. Sarcopenia. Cruz-Jentoft AJ, Sayer AA. Lancet (London, England). 2019;393(10191):2636-2646. doi:10.1016/S0140-6736(19)31138-9.
2. Comparative Effectiveness of Exercise and Protein-Based Interventions on Muscle Strength, Mass, and Function in Sarcopenia: A Systematic Review and Network Meta-Analysis. Yan R, Jia S, Lu D, et al. The Journal of Nutrition, Health & Aging. 2025;29(12):100718. doi:10.1016/j.jnha.2025.100718.
3. Sarcopenia: A Time for Action. An SCWD Position Paper. Bauer J, Morley JE, Schols AMWJ, et al. Journal of Cachexia, Sarcopenia and Muscle. 2019;10(5):956-961. doi:10.1002/jcsm.12483.
4. Current and Investigational Medications for the Treatment of Sarcopenia. Rolland Y, Dray C, Vellas B, Barreto PS. Metabolism: Clinical and Experimental. 2023;149:155597. doi:10.1016/j.metabol.2023.155597.
5. Sarcopenia. Sayer AA, Cooper R, Arai H, et al. Nature Reviews. Disease Primers. 2024;10(1):68. doi:10.1038/s41572-024-00550-w.
6. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Age and Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.
7. Sarcopenia: An Overview of Emerging Therapies and Pathophysiological Insights in Age-Related Skeletal Muscle Decline. Mishra D, Mohapatra L. Biochemical Pharmacology. 2026;248:117813. doi:10.1016/j.bcp.2026.117813.
8. Therapeutic Advances in Sarcopenia Management: From Traditional Interventions to Personalized Medicine. Liu X, Chen X, Cui J. Clinical Nutrition (Edinburgh, Scotland). 2025;51:187-197. doi:10.1016/j.clnu.2025.06.007.
9. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. Espinoza SE, Khosla S, Baur JA, de Cabo R, Musi N. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):53-60. doi:10.1093/gerona/glad034.
10. Energy-Replenishing, Mitochondria-Targeted Hydrogel Microspheres Mitigate Sarcopenia via Cellular Senescence Amelioration. Bao W, Liu S, Du C, et al. Journal of Controlled Release : Official Journal of the Controlled Release Society. 2026;391:114595. doi:10.1016/j.jconrel.2025.114595.
11. Frailty in Older Adults. Kim DH, Rockwood K. The New England Journal of Medicine. 2024;391(6):538-548. doi:10.1056/NEJMra2301292.
12. Creatine Supplementation During Resistance Training in Older Adults-a Meta-Analysis. Devries MC, Phillips SM. Medicine and Science in Sports and Exercise. 2014;46(6):1194-203. doi:10.1249/MSS.0000000000000220.
13. Creatine Supplementation for Optimization of Physical Function in the Patient at Risk of Functional Disability: A Systematic Review and Meta-Analysis. Davies TW, Watson N, Pilkington JJ, et al. JPEN. Journal of Parenteral and Enteral Nutrition. 2024;48(4):389-405. doi:10.1002/jpen.2607.
14. Impact of creatine supplementation in combination with resistance training on lean mass in the elderly. Pinto CL, Botelho PB, Carneiro JA, Mota JF. Journal of Cachexia, Sarcopenia and Muscle. 2016;7(4):413-21. doi:10.1002/jcsm.12094.
15. The Role of Omega-3 Polyunsaturated Fatty Acids on Sarcopenia and Aging Muscle. Varamini B, Yang JO, Merry BJ, Dau DJ. International Journal of Environmental Research and Public Health. 2026;23(3):355. doi:10.3390/ijerph23030355.
16. The Effect of Omega-3 Fatty Acids on Sarcopenia: Mechanism of Action and Potential Efficacy. Therdyothin A, Phiphopthatsanee N, Isanejad M. Marine Drugs. 2023;21(7):399. doi:10.3390/md21070399.
17. Long-Chain N -3 Polyunsaturated Fatty Acids for the Management of Age- And Disease-Related Declines in Skeletal Muscle Mass, Strength and Physical Function. Phillips N, Gray SR, Combet E, Witard OC. Current Opinion in Clinical Nutrition and Metabolic Care. 2024;27(2):98-105. doi:10.1097/MCO.0000000000000986.
18. Fish Oil-Derived N-3 PUFA Therapy Increases Muscle Mass and Function in Healthy Older Adults. Smith GI, Julliand S, Reeds DN, et al. The American Journal of Clinical Nutrition. 2015;102(1):115-22. doi:10.3945/ajcn.114.105833.
19. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial. Rooks D, Swan T, Goswami B, et al. JAMA Network Open. 2020;3(10):e2020836. doi:10.1001/jamanetworkopen.2020.20836.
20. New Molecules and Indications for GLP-1 Medicines. Gonzalez-Rellan MJ, Drucker DJ. JAMA. 2025;334(14):1231-1234. doi:10.1001/jama.2025.14392.
21. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Pratley RE, Denham DS, Trivedi R, et al. Nature Medicine. 2026;32(7):2673-2678. doi:10.1038/s41591-026-04440-4.
22. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta‐Analysis. Prokopidis K, Moriarty F, Bahat G, et al. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(3):e13799. doi:10.1002/jcsm.13799.
23. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Chen LK, Hsiao FY, Akishita M, et al. Nature Aging. 2025;5(11):2164-2175. doi:10.1038/s43587-025-01004-y.
24. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Locatelli JC, Costa JG, Haynes A, et al. Diabetes Care. 2024;47(10):1718-1730. doi:10.2337/dci23-0100.
25. The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era. Lieberman DE, Aslan DH, Heymsfield SB. JAMA. 2026;:2848640. doi:10.1001/jama.2026.5537.
26. Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand. Zanker J, Sim M, Anderson K, et al. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(1):142-156. doi:10.1002/jcsm.13115.
27. Effects of Creatine Supplementation With and Without Exercise and Diet Intervention on Body Composition, Cognitive Function, and Markers of Health in Middle-Aged and Older Adults. Chun J, Liu Y, Kibler GL, et al. Journal of the International Society of Sports Nutrition. 2026;23(sup1):2716273. doi:10.1080/15502783.2026.2716273.
28. Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis. Busk-Cirera L, Carlsen IØ, Madsen LB, et al. Diabetes, Obesity & Metabolism. 2026;28(9):7737-7751. doi:10.1111/dom.71006.
29. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Mozaffarian D, Agarwal M, Aggarwal M, et al. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.
30. Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies. Neeland IJ, Linge J, Birkenfeld AL. Diabetes, Obesity & Metabolism. 2024;26 Suppl 4:16-27. doi:10.1111/dom.15728.